BRIEF published on 11/04/2025 at 07:35, 1 month ago R. STAHL Reports Q3 2025 Results Amidst Subdued Demand Cost-cutting Measures Sales Forecast EBITDA Growth Nine-month Figures Demand Decrease
PRESS RELEASE published on 11/04/2025 at 07:30, 1 month ago R. STAHL publishes nine-month figures – demand remains subdued R. STAHL reports subdued demand with a 12.1% sales decrease in the first nine months of 2025. EBITDA pre exceptionals down to €20.2 million. Company maintains sales forecast of €320-330 million for 2025 Sales EBITDA Forecast R. STAHL Demand
BRIEF published on 09/16/2025 at 10:36, 2 months 18 days ago R. STAHL Initiates Leadership Transition Leadership Transition R. Stahl AG Corporate Strategy Management Change Dr. Claus Bischoff
PRESS RELEASE published on 09/16/2025 at 10:31, 2 months 18 days ago R. STAHL preparing gradual leadership transition R. STAHL AG announces gradual leadership transition with Dr. Claus Bischoff appointed as additional Executive Board member and Deputy CEO effective 1 October 2025, succeeding CEO Dr. Mathias Hallmann on 1 January 2026 Leadership Transition R. Stahl AG Corporate Strategy CEO Succession Dr. Claus Bischoff
BRIEF published on 09/16/2025 at 10:30, 2 months 18 days ago R. STAHL Announces Management Transition Executive Board R. STAHL Management Change Claus Bischoff Dr. Mathias Hallmann
PRESS RELEASE published on 09/16/2025 at 10:25, 2 months 18 days ago EQS-Adhoc: R. STAHL announces planned change in management of the company R. STAHL announces Dr. Claus Bischoff as new Chairman of the Executive Board effective Jan 1, 2026, succeeding Dr. Mathias Hallmann by Dec 31, 2025. Dr. Hallmann to support transition process Succession Planning R. STAHL Management Change Dr. Mathias Hallmann Dr. Claus Bischoff
BRIEF published on 08/07/2025 at 07:35, 3 months 28 days ago R. STAHL Reports Decline in H1 2025 Financial Performance Forecast Adjustment Sales Decline R. STAHL Half-year Results 2025 Profitability Impact
PRESS RELEASE published on 08/07/2025 at 07:30, 3 months 28 days ago R. STAHL publishes half-year figures – sales and profitability below prior year – forecast for 2025 adjusted R. STAHL publishes half-year figures with sales and profitability below prior year, adjusting forecast for 2025 due to global economic uncertainties Sales Profitability Forecast R. STAHL Half-Year Figures
BRIEF published on 07/28/2025 at 13:01, 4 months 7 days ago R. Stahl AG Revises 2025 Forecast Amid Economic Challenges Sales Decline R. STAHL Economic Challenges EBITDA Adjustment 2025 Forecast
PRESS RELEASE published on 07/28/2025 at 12:56, 4 months 7 days ago EQS-Adhoc: R. STAHL publishes preliminary figures for the first half of 2025 and adjusts forecast for full-year 2025 R. STAHL revises full-year 2025 forecast after challenging economic environment impacts preliminary first half figures Forecast Economic Environment Preliminary Figures R. STAHL 2025
Published on 12/05/2025 at 02:35, 3 hours 35 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 5 hours 10 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 5 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 10 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 2 hours 39 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 19 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 9 hours 44 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 55 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 59 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 12 hours 10 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 25 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 26 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 9 minutes ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago Declaration of voting rights at the end of November 2025
